Lotronex

Active Ingredient(s): Alosetron
FDA Approved: * February 9, 2000
Pharm Company: * GLAXOSMITHKLINE
Category: Irritable Bowel Syndrome

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Lotronex Overview

Alosetron (original brand name: Lotronex /lotrnks/ LOH-tron-eks; originator: GSK) is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome (IBS) in women only. It is currently marketed by Prometheus Laboratories Inc. (San Diego). Alosetron was withdrawn from the market in 2000 owing to the occurrence of serious life-threatening gastrointestinal adverse effects, but was reintroduced in 2002 with availability and use restricted. Contents 1 Approv...

Read more Lotronex Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Alosetron

Recent Lotronex Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Alosetron
  • Tablet: 0.5mg, 1mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Lotronex: (4 results)

Sorted by National Drug Code
  • 54766-894 Lotronex .5 mg Oral Tablet by Sebela Pharmaceuticals Inc.
  • 54766-895 Lotronex 1 mg Oral Tablet by Sebela Pharmaceuticals Inc.
  • 65483-894 Lotronex 0.5 mg Oral Tablet by Prometheus Laboratories Inc.
  • 65483-895 Lotronex 1 mg Oral Tablet by Prometheus Laboratories Inc.

Other drugs which contain Alosetron or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 16 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA